DSIP Australia

DSIP Australia. DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide studied in laboratory research as a neuromodulatory peptide referenced across sleep-regulation and slow-wave-EEG research literature. The Elite AU Peptides DSIP is independently HPLC-tested above 99% purity by Janoshik; the certificate of analysis is published on this page and in the lab-reports library, with the measured number and an independently verifiable Janoshik key.

Stocked and dispatched AU-domestic in 5 mg and 10 mg lyophilised vials, AUD pricing. Every batch is held until the independent HPLC report comes back within our acceptance threshold; nothing is listed without a certificate on file. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, not TGA-approved.

DSIP (CAS 62568-57-4; molecular formula C35H48N10O15, average molecular weight ≈ 849 g/mol) is the amphiphilic nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It was originally isolated from cerebral venous blood and characterised as a delta-electroencephalogram-inducing factor by Schoenenberger and Monnier (PNAS, 1977); its nonapeptide sequence was determined and confirmed by synthesis in the follow-up work of Schoenenberger and colleagues (Pflügers Archiv, 1978).

In neuromodulation research, DSIP’s defining readout is enhancement of slow-wave (delta) and spindle EEG activity in animal models, positioning it as a probe of endogenous sleep-EEG and circadian modulation. The review literature — foundationally Graf and Kastin (Neuroscience & Biobehavioral Reviews, 1984) — also documents “extra-sleep” effects on neurotransmitter systems, hormone release, and stress and circadian pathways.

DSIP is characterised in the literature as a diffusible neuropeptide modulator rather than a ligand with a single well-defined cloned receptor, which is why it is studied as a broad neuromodulatory research tool rather than a selective receptor agonist. It remains a reference peptide in sleep-EEG and neuroendocrine research contexts.

The peptide’s amphiphilic character — a hydrophobic tryptophan alongside polar and acidic residues — is a defining structural feature noted throughout the handling and analytical literature, and it underlies the compound’s water solubility. Beyond its slow-wave-EEG readout, DSIP is also referenced for reported interactions with neurotransmitter and neuroendocrine systems, which is why the review literature describes a broad rather than a narrow research profile and treats it as a general neuromodulatory probe.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, sleep-aid, or human-use claim about this product. DSIP is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for protocol-specific reference values.

Reconstitute the lyophilised DSIP vial with bacteriostatic water for laboratory handling. The peptide is amphiphilic and water-soluble; add the diluent slowly down the vial wall and swirl gently rather than shaking. A 5 mg vial reconstituted in 2 mL of bacteriostatic water yields a 2.5 mg/mL working stock — adjust to your protocol’s target concentration.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.